New AAM Chief Sets Out Priorities
US Industry Body Head Says Full Promise Of Biosimilars ‘Not Being Realized’
The AAM’s new CEO, Dan Leonard, has set out his priorities for the industry association, highlighting current industry challenges as well as throwing light on how generics can be the “bridge” to a COVID-19 vaccine.
You may also be interested in...
Executive orders signed by Joe Biden in the first days of his presidency to support the US pandemic response – including calling for a plan to bolster domestic manufacturing capabilities – have received a warm welcome from the AAM.
AAM president and CEO Dan Leonard has written to the US Congress with five major legislative suggestions, including enforcing changes to Medicare part B and Medicare part D.
US off-patent industry association the AAM has welcomed the prospect of working with the incoming Biden-Harris administration, emphasizing that there is “more to be done” to improve generic and biosimilar utilization and uptake.